TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer

BACKGROUND: In preclinical studies, the expression of vascular endothelial growth factor (VEGF) in hormone receptor-positive breast cancer is associated with estrogen-independent tumor growth and resistance to endocrine therapies. This study investigated whether the addition of bevacizumab, a monocl...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaklavas, Christos, Roberts, Brian S., Varley, Katherine E., Lin, Nancy U., Liu, Minetta C., Rugo, Hope S., Puhalla, Shannon, Nanda, Rita, Storniolo, Anna Maria, Carey, Lisa A., Saleh, Mansoor N., Li, Yufeng, Delossantos, Jennifer F., Grizzle, William E., LoBuglio, Albert F., Myers, Richard M., Forero-Torres, Andres
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027068/
https://www.ncbi.nlm.nih.gov/pubmed/32070401
http://dx.doi.org/10.1186/s13058-020-01258-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027068/
https://www.ncbi.nlm.nih.gov/pubmed/32070401
http://dx.doi.org/10.1186/s13058-020-01258-x

Ejemplares similares